Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Schizophrenia

Free Subscription Articles published in J Clin Psychopharmacol Retrieve available abstracts of 77 articles: HTML format

Single Articles

April 2026
1. GROVER S, Yadav N, Sutail H, Chakrabarti S, et al
   Hepatic Steatosis, Hepatic Fibrosis, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Schizophrenia Patients: An Exploratory Study From India.
   J Clin Psychopharmacol. 2026 Apr 3. doi: 10.1097/JCP.0000000000002159.
   PubMed     Abstract available
   
   
   
2. CALLI SY, Fidan YS, Kizilsert A, Izci F, et al
   Comparison of Standard and Two-Injection Start Regimens of Long-Acting Injectable Aripiprazole Monohydrate in Female Patients With Schizophrenia and Bipolar Disorder: A Retrospective Cohort Study.
   J Clin Psychopharmacol. 2026 Apr 2. doi: 10.1097/JCP.0000000000002183.
   PubMed     Abstract available
   
   
   March 2026
3. ALABAKU O, Olfson M, Stroup TS, Gerhard T, et al
   The Use of VMAT2 Inhibitors for Tardive Dyskinesia.
   J Clin Psychopharmacol. 2026;46:189-194.
   PubMed     Abstract available
   
   
   February 2026
4. MUKAI Y, Kost J, Snow-Adami L, Reed J, et al
   Phase 2b Trial of the PDE10A Inhibitor MK-8189 in People With an Acute Episode of Schizophrenia.
   J Clin Psychopharmacol. 2026 Feb 23. doi: 10.1097/JCP.0000000000002152.
   PubMed     Abstract available
   
   
   
5. CHOENKLANG C, Rattanapitoon SK, La N, Rattanapitoon NK, et al
   Beyond Clozapine: Addressing Broader Metabolic Burden in Treatment-Resistant Schizophrenia.
   J Clin Psychopharmacol. 2026 Feb 11. doi: 10.1097/JCP.0000000000002133.
   PubMed    
   
   
   
6. JOHN AP, Prajapati H, Dragovic M
   Reply to "Beyond Clozapine: Addressing Broader Metabolic Burden in Treatment-Resistant Schizophrenia".
   J Clin Psychopharmacol. 2026 Feb 4. doi: 10.1097/JCP.0000000000002134.
   PubMed    
   
   
   January 2026
7. HSIEH MH, Huang HH, Huang SC, Hou PY, et al
   Nonabsorption of Paliperidone Palmitate Suspension Two Months After Administration in a Patient With Schizophrenia and Keloid: A Case Report.
   J Clin Psychopharmacol. 2026 Jan 28. doi: 10.1097/JCP.0000000000002130.
   PubMed    
   
   
   
8. KEMPINGER LM, Wiss FM, Lampert ML, Sociu A, et al
   P-Glycoprotein-Related Interactions With Paliperidone May Result in Subtherapeutic Drug Levels and Clinical Exacerbation of Schizophrenia: A Case Report.
   J Clin Psychopharmacol. 2026 Jan 26. doi: 10.1097/JCP.0000000000002131.
   PubMed    
   
   
   
9. ZHAND N, Joober R, Labelle A, Attwood D, et al
   Efficacy of Low-Dose Adjunctive Methylphenidate Extended-Release on Cognition and Functioning in Individuals With Schizophrenia: A Randomized Open-Label Trial.
   J Clin Psychopharmacol. 2026 Jan 26. doi: 10.1097/JCP.0000000000002132.
   PubMed     Abstract available
   
   
   
10. DE LEON J, de Leon VC, Sanz EJ, De Las Cuevas C, et al
    Clozapine and Suicide in VigiBase: Most Important Fatal Outcome in Young Males and Differences Between Attempted and Completed Suicide.
    J Clin Psychopharmacol. 2026;46:5-15.
    PubMed     Abstract available
    
    
    
11. FLANAGAN RJ, Rogers JP, Sanchez PLV, Evans L, et al
    Adverse Reactions to Clozapine: Plasma Clozapine in Relation to Smoking Status.
    J Clin Psychopharmacol. 2026;46:36-43.
    PubMed     Abstract available
    
    
    November 2025
12. DE LAS CUEVAS C, Sanz EJ, de Leon J
    Fatal Outcomes in Use of Clozapine: A VigiBase Study of 6402 Women and 11,222 Men.
    J Clin Psychopharmacol. 2025;45:547-553.
    PubMed     Abstract available
    
    
    October 2025
13. SPIEGEL DR, Wallace T, Kozlova V, Hoff M, et al
    Betamethasone-Associated Psychosis in a Pregnant Woman Diagnosed With Schizophrenia.
    J Clin Psychopharmacol. 2025 Oct 29. doi: 10.1097/JCP.0000000000002101.
    PubMed    
    
    
    
14. WU ZW, Chen SW, Tsai TH, Tsai JH, et al
    Persistent Hiccups Associated With Long-Acting Injectable Aripiprazole in a Man With Schizophrenia.
    J Clin Psychopharmacol. 2025 Oct 15. doi: 10.1097/JCP.0000000000002052.
    PubMed    
    
    
    September 2025
15. KUMAR V, Ramesh V, Manchegowda S, Krishna Prasad M, et al
    Levodopa Augmentation of Antipsychotics for Persistent Negative Symptoms in Schizophrenia: An Open-Label Study.
    J Clin Psychopharmacol. 2025 Sep 10. doi: 10.1097/JCP.0000000000002084.
    PubMed    
    
    
    
16. PETERS SJ, Staninska A, Lehmann I, Gouzoulis-Mayfrank E, et al
    Antipsychotic Treatment Approaches in Schizophrenia Spectrum and Other Psychotic Disorders: Prescription Patterns in Eight Different Diagnostic Groups.
    J Clin Psychopharmacol. 2025 Sep 5. doi: 10.1097/JCP.0000000000002079.
    PubMed     Abstract available
    
    
    
17. DA SILVA TM, Vianna DRB, Meulman J, Turncliff R, et al
    Multicenter Bioavailability Study of Long-Acting Paliperidone in Patients With Schizophrenia or Schizoaffective Disorder.
    J Clin Psychopharmacol. 2025 Sep 4. doi: 10.1097/JCP.0000000000002078.
    PubMed     Abstract available
    
    
    August 2025
18. PIRES AC, Faria I, Bajouco M, Mota D, et al
    Clozapine-Resistant Schizophrenia and Wolff-Parkinson-White Syndrome: A Case Report.
    J Clin Psychopharmacol. 2025 Aug 22. doi: 10.1097/JCP.0000000000002055.
    PubMed    
    
    
    
19. JOHN AP, Prajapati H, Dragovic M
    Metabolic Problems Among People With Treatment-Resistant Schizophrenia are Not Unique to Clozapine.
    J Clin Psychopharmacol. 2025 Aug 15. doi: 10.1097/JCP.0000000000002058.
    PubMed     Abstract available
    
    
    
20. GONZALEZ-OJEDA LM, Santamaria-Garcia H, Villegas LM, Trujillo-Llano C, et al
    Global Insights Into Antipsychotic Research: Bridging Trends and Gaps in Schizophrenia Care (2000-2024).
    J Clin Psychopharmacol. 2025 Aug 14. doi: 10.1097/JCP.0000000000002062.
    PubMed     Abstract available
    
    
    
21. GOFF DC
    Response to the Letter to the Editor by Dr Reynolds, Xanomeline/Trospium Combination: Not Non-Dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia.
    J Clin Psychopharmacol. 2025 Aug 11. doi: 10.1097/JCP.0000000000002029.
    PubMed    
    
    
    
22. CHANG D, See YM, Yee JY, Law C, et al
    Obesity Associated With Symptomatic Remission in Clozapine-Treated Individuals With Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2025 Aug 11. doi: 10.1097/JCP.0000000000002048.
    PubMed     Abstract available
    
    
    
23. KOBAYASHI Y, Ichinose M, Terui T, Hoshino H, et al
    Predictive Validity of the 5-Factor PANSS Model in Acute Schizophrenia: Early Response to Aripiprazole and Brexpiprazole.
    J Clin Psychopharmacol. 2025 Aug 1. doi: 10.1097/JCP.0000000000002040.
    PubMed     Abstract available
    
    
    June 2025
24. NOE G, Gaba A, Munjal S
    Recurrent Ziconotide-Associated Delirium and Psychosis: A Case Report.
    J Clin Psychopharmacol. 2025 Jun 13. doi: 10.1097/JCP.0000000000002021.
    PubMed    
    
    
    
25. REYNOLDS GP
    Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia.
    J Clin Psychopharmacol. 2025 Jun 6. doi: 10.1097/JCP.0000000000002028.
    PubMed    
    
    
    May 2025
26. JOGI L, Praveen P, Shibu A, Narasimhappa K, et al
    The Impact of Therapeutic Drug Monitoring on Clozapine Dosing and Clinical Outcome in a Tertiary Care Center in India: A Retrospective Study.
    J Clin Psychopharmacol. 2025;45:251-257.
    PubMed     Abstract available
    
    
    April 2025
27. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
    Plasma Clozapine in Treatment Refractory Schizophrenia: What Is the Target Range?
    J Clin Psychopharmacol. 2025 Apr 9. doi: 10.1097/JCP.0000000000002007.
    PubMed     Abstract available
    
    
    
28. COLIJN MA
    Clozapine Use Among Individuals With Schizophrenia Occurring on the Background of Intellectual Disability and Rare Genetic Variation: A Retrospective Chart Review.
    J Clin Psychopharmacol. 2025 Apr 7. doi: 10.1097/JCP.0000000000002000.
    PubMed     Abstract available
    
    
    
29. KIKUCHI Y, Sakata M, Ikawa K, Kume D, et al
    Weekly Changes in the Clozapine Concentration-to-Dose Ratio During Clozapine Titration in Japanese Patients With Schizophrenia.
    J Clin Psychopharmacol. 2025 Apr 7. doi: 10.1097/JCP.0000000000002003.
    PubMed     Abstract available
    
    
    March 2025
30. PACILIO RM, Geller JA
    Persistent Psychosis Associated With Intravenous Ketamine in a Patient Using Cannabis: A Case Report and Literature Review.
    J Clin Psychopharmacol. 2025 Mar 27. doi: 10.1097/JCP.0000000000001995.
    PubMed    
    
    
    
31. YE CW, Lin CH, Wang SJ
    Olanzapine-Associated Hyperbilirubinemia in an Adolescent With Autistic Spectrum Disorder Comorbid With Schizophrenia: A Case Report.
    J Clin Psychopharmacol. 2025 Mar 26. doi: 10.1097/JCP.0000000000001974.
    PubMed    
    
    
    February 2025
32. DODDI SR, Pham F, Wineke J, Marano C, et al
    Protracted Psychiatric Complications Including Psychosis in a Middle-Aged Man After COVID-19 Vaccination: A Case Report.
    J Clin Psychopharmacol. 2025 Feb 10. doi: 10.1097/JCP.0000000000001969.
    PubMed    
    
    
    
33. ELOMA-ATA A, Wafy F, Parikh A, Tusher A, et al
    A Case of Hypothermia Associated With the Use of Multiple Antipsychotics in a Patient With Late-Onset Schizophrenia.
    J Clin Psychopharmacol. 2025 Feb 7. doi: 10.1097/JCP.0000000000001961.
    PubMed    
    
    
    
34. GOFF DC
    At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy).
    J Clin Psychopharmacol. 2025 Feb 6. doi: 10.1097/JCP.0000000000001959.
    PubMed    
    
    
    January 2025
35. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
    Clozapine Dosage in Treatment-Refractory Schizophrenia: A Reply to Dr Grover and Colleagues.
    J Clin Psychopharmacol. 2025 Jan 14. doi: 10.1097/JCP.0000000000001955.
    PubMed    
    
    
    
36. OLMOS I, Ricciardi C, Mato M, Guevara N, et al
    Optimization of Clozapine Treatment: Study of Variables Affecting Response in Uruguayan Patients With Schizophrenia.
    J Clin Psychopharmacol. 2025;45:20-27.
    PubMed     Abstract available
    
    
    December 2024
37. EL JABIRY SE, Benkarroum F, Barrimi M, Elghazouani F, et al
    Risperidone-Associated Stuttering in Patient With Schizophrenia: A Case Report.
    J Clin Psychopharmacol. 2024 Dec 31. doi: 10.1097/JCP.0000000000001950.
    PubMed    
    
    
    
38. HOOBERMAN AJ, Martinez NJ, Stojcevski M, Wechsler B, et al
    A Case of Tacrolimus-Associated Psychosis.
    J Clin Psychopharmacol. 2024 Dec 31. doi: 10.1097/JCP.0000000000001956.
    PubMed    
    
    
    
39. BUESKING SC, Kriz CR, Jarvis SP, Nelson LA, et al
    Recognition of Clozapine-Associated Eosinopenia in Patients With Treatment-Resistant Schizophrenia: A Report of 3 Cases and Literature Review.
    J Clin Psychopharmacol. 2024 Dec 17. doi: 10.1097/JCP.0000000000001947.
    PubMed    
    
    
    
40. TAKEUCHI H, Uchida H
    Efficacy and Safety of Dose Increase From 40 mg/d to 80 mg/d of Lurasidone in Patients With Schizophrenia: A Post Hoc Analysis of Extension Trial.
    J Clin Psychopharmacol. 2024 Dec 2. doi: 10.1097/JCP.0000000000001943.
    PubMed     Abstract available
    
    
    November 2024
41. O'CONNELL P, Alsaffar M
    The Treatment of Iatrogenic Anorgasmia in a Male Patient on Clozapine for Treatment-Resistant Schizophrenia: The Role of Pseudoephedrine.
    J Clin Psychopharmacol. 2024 Nov 12. doi: 10.1097/JCP.0000000000001930.
    PubMed    
    
    
    
42. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
    Effect of Valproate Coprescription on Clozapine Pharmacokinetics in Clinical Practice.
    J Clin Psychopharmacol. 2024;44:561-569.
    PubMed     Abstract available
    
    
    
43. GURCAN G, Atalay B, Deveci E
    Clozapine-Associated Sialorrhea: A Literature Review.
    J Clin Psychopharmacol. 2024;44:570-575.
    PubMed     Abstract available
    
    
    
44. LOCHMANN VAN BENNEKOM MWH, Gijsman HJ, IntHout J, Verkes RJ, et al
    Antipsychotic Polypharmacy in Time Course: Evidence for a Cross-titration Trap.
    J Clin Psychopharmacol. 2024;44:545-550.
    PubMed     Abstract available
    
    
    October 2024
45. PEREZ-SAGASETA DE ILURDOZ I, Aparicio-Dominguez A, Yelmo-Cruz S, Cardenes-Moreno C, et al
    alpha-PVP Associated Psychosis: A Case Report.
    J Clin Psychopharmacol. 2024 Oct 11. doi: 10.1097/JCP.0000000000001918.
    PubMed    
    
    
    September 2024
46. MITOMA R, Hirano S, Nakao T
    Successful Management of ECT-Resistant Interictal Psychosis With Clozapine: A Case Report.
    J Clin Psychopharmacol. 2024;44:527-528.
    PubMed    
    
    
    
47. DI LISI A, Pupo S, Menchetti M, Pelizza L, et al
    Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice.
    J Clin Psychopharmacol. 2024;44:502-508.
    PubMed     Abstract available
    
    
    
48. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
    Plasma Clozapine and N -Desmethylclozapine (Norclozapine) Concentrations and the Clozapine/Norclozapine Ratio : Effect of Dose, Sex, and Cigarette Smoking.
    J Clin Psychopharmacol. 2024;44:492-501.
    PubMed     Abstract available
    
    
    August 2024
49. BUCHANAN RW, Werkheiser AE, Michel H, Zaranski J, et al
    Prebiotic Treatment in People With Schizophrenia.
    J Clin Psychopharmacol. 2024 Aug 16. doi: 10.1097/JCP.0000000000001899.
    PubMed     Abstract available
    
    
    July 2024
50. HAUSER RA, Barkay H, Fernandez HH, Jimenez-Shahed J, et al
    Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
    J Clin Psychopharmacol. 2024;44:386-396.
    PubMed     Abstract available
    
    
    
51. GOUDA M, Abe M, Watanabe Y, Kato TA, et al
    Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association.
    J Clin Psychopharmacol. 2024;44:378-385.
    PubMed     Abstract available
    
    
    
52. PACILIO RM, Dalack GW
    Asthma and Atypical Antipsychotics: A Systematic Literature Review and Case Report of Respiratory Side Effects With Lurasidone, Cariprazine, and Lumateperone.
    J Clin Psychopharmacol. 2024;44:436-437.
    PubMed    
    
    
    May 2024
53. KARAL BN, Ozdemir YE, Karayagmurlu A
    The Management of Very Early-Onset Schizophrenia With an Olanzapine and Amisulpride Combination.
    J Clin Psychopharmacol. 2024 May 2. doi: 10.1097/JCP.0000000000001853.
    PubMed    
    
    
    
54. OKADA Y, Inada K, Akazawa M
    Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.
    J Clin Psychopharmacol. 2024;44:263-271.
    PubMed     Abstract available
    
    
    
55. DE LEON J
    Can Slow Personalized Titration Using C-Reactive Protein Monitoring Decrease the High Rates and Mortality of Clozapine-Associated Myocarditis Seen in Some Countries? A Call for Research.
    J Clin Psychopharmacol. 2024;44:212-219.
    PubMed     Abstract available
    
    
    April 2024
56. SCALA M, Martinez Trapote P, Rodriguez-Jimenez R, Pecorino B, et al
    Managing a Treatment-Resistant Schizophrenia Spectrum Disorder With a Hormonal Twist in a Female Patient: A Case Report of a Progestin-Only Pill.
    J Clin Psychopharmacol. 2024 Apr 9. doi: 10.1097/JCP.0000000000001836.
    PubMed    
    
    
    March 2024
57. KORKMAZ SA, Koca E, Yilmaz O, Ozbek T, et al
    Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders.
    J Clin Psychopharmacol. 2024 Mar 5. doi: 10.1097/JCP.0000000000001837.
    PubMed     Abstract available
    
    
    
58. NAGANO M, Susuta Y, Masui H, Watanabe Y, et al
    Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
    J Clin Psychopharmacol. 2024;44:107-116.
    PubMed     Abstract available
    
    
    February 2024
59. MORI Y, Watanabe K, Suzuki Y, Ono H, et al
    Clozapine-Associated Myocarditis in a Patient With Schizophrenia Taking Lemborexant: A Case Report.
    J Clin Psychopharmacol. 2024 Feb 8. doi: 10.1097/JCP.0000000000001817.
    PubMed    
    
    
    
60. DIMA A, Abdelsamie A, Clark-Castillo R, Webb-Wilson H, et al
    Overcoming Obstacles to Clozapine Treatment: A Case of Clozapine Rechallenge in ECT-Resistant Schizophrenia With Catatonic Features.
    J Clin Psychopharmacol. 2024 Feb 5. doi: 10.1097/JCP.0000000000001819.
    PubMed    
    
    
    January 2024
61. WATANABE M, Misawa F, Takeuchi H
    Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study.
    J Clin Psychopharmacol. 2024 Jan 26. doi: 10.1097/JCP.0000000000001804.
    PubMed     Abstract available
    
    
    
62. KJELBY E, Gjestad R, Fathian F, Sinkeviciute I, et al
    Reply to a Letter to the Editors From Dr de Souza and colleagues: "Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity".
    J Clin Psychopharmacol. 2024;44:76-78.
    PubMed    
    
    
    
63. DE SOUZA JUNIOR SA, Cavalcante da Rocha ME, Marques Andrade AG, Fernandes de Moraes CL, et al
    Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity.
    J Clin Psychopharmacol. 2024;44:74-76.
    PubMed    
    
    
    
64. MOHAMMAD-GHOLIZAD F, Karimzadeh I, Moghimi-Sarani E, Arshadi M, et al
    Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial
    J Clin Psychopharmacol. 2024;44:9-15.
    PubMed     Abstract available
    
    
    
65. KARACAM DOGAN M, Yildiz FG, Temucin CM, Ertugrul A, et al
    Effects of Clozapine on Cortical Inhibition: A Transcranial Magnetic Stimulation Follow-up Study.
    J Clin Psychopharmacol. 2024;44:16-24.
    PubMed     Abstract available
    
    
    November 2023
66. LEE MA, Cola P, Jayathilake K, Meltzer HY, et al
    Reply to Dr Yucel's Comments on the Article "Long-term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555-556.
    PubMed    
    
    
    
67. YUCEL A
    Critical Feedback on Article by Lee and Colleagues: "Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555.
    PubMed    
    
    
    
68. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis?: A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023;43:551-553.
    PubMed    
    
    
    
69. MAGISTRI C, Mellini C
    Clozapine-Associated Agranulocytosis: A Systematic Review. Is It Really So Frighteningly Common?
    J Clin Psychopharmacol. 2023;43:527-533.
    PubMed     Abstract available
    
    
    
70. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis: A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023;43:511-513.
    PubMed     Abstract available
    
    
    September 2023
71. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis? A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023 Sep 29. doi: 10.1097/JCP.0000000000001766.
    PubMed    
    
    
    
72. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis. A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023 Sep 7. doi: 10.1097/JCP.0000000000001758.
    PubMed     Abstract available
    
    
    
73. TKACH N, Opler DJ
    A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis.
    J Clin Psychopharmacol. 2023;43:481-482.
    PubMed    
    
    
    
74. DE LIMA DN JR, Frota IJ, Macedo DS, Sanders LLO, et al
    Alpha Lipoic Acid for Schizophrenia: Future Investigations With Low Doses and Treatment-Resistant Patients-Reply to Letter by Kishi and Colleagues.
    J Clin Psychopharmacol. 2023;43:478-479.
    PubMed    
    
    
    
75. KISHI T, Sakuma K, Miura G, Ito Y, et al
    Alpha Lipoic Acid for Schizophrenia: A Systematic Review and Meta-analysis.
    J Clin Psychopharmacol. 2023;43:477-478.
    PubMed    
    
    
    
76. BROTHWOOD PL, Husain M, Pinson J, Oloyede E, et al
    Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report.
    J Clin Psychopharmacol. 2023;43:472-474.
    PubMed    
    
    
    
77. JOGI L, Subu O, Jaishankar P, Kumar V, et al
    Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report.
    J Clin Psychopharmacol. 2023;43:468-469.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum